Mirum reports Phase 3 success for its acquired hepatitis D therapy

Mirum Pharmaceuticals announced that its recently acquired chronic hepatitis delta drug met its primary endpoint in a Phase 3 trial.

The study tested a once-weekly 300 mg injection, and more than half of patients achieved the predefined virologic response, indicating strong efficacy.

The positive outcome adds momentum to Mirum's pipeline and points to a potential regulatory filing and commercial launch, improving the company’s growth outlook.